Profile data is unavailable for this security.
About the company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2019
- Employees82.00
- LocationArtiva Biotherapeutics Inc5505 Morehouse DriveSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 267-4467
- Fax+1 (302) 269-3855
- Websitehttps://www.artivabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | 34.84m | -74.62m | 242.90m | 123.00 | -- | 231.91 | -- | 6.97 | -0.6129 | -0.6129 | 0.286 | 0.0085 | 0.1611 | -- | 69.67 | 283,227.70 | -34.51 | -61.68 | -50.38 | -81.35 | -- | -- | -214.19 | -622.19 | -- | -- | 0.9604 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -4.08m | 243.14m | 20.00 | -- | 2.20 | -- | -- | -0.3861 | -0.3861 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -1.13 | -38.44 | -1.22 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| aTyr Pharma Inc | 235.00k | -63.82m | 250.15m | 56.00 | -- | 3.46 | -- | 1,064.46 | -0.9365 | -0.9365 | 0.0034 | 0.8617 | 0.0022 | -- | 0.12 | 4,196.43 | -58.90 | -45.45 | -67.15 | -52.74 | -- | -- | -27,155.32 | -784.19 | -- | -- | 0.0233 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Abeona Therapeutics Inc | 0.00 | -71.03m | 250.79m | 84.00 | -- | 5.49 | -- | -- | -2.29 | -2.29 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -76.10 | -53.22 | -88.88 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2895 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Lyell Immunopharma Inc | 63.00k | -203.99m | 255.93m | 224.00 | -- | 0.4431 | -- | 4,062.44 | -0.8013 | -0.8013 | 0.0003 | 2.07 | 0.00009 | -- | -- | 281.25 | -28.85 | -- | -30.32 | -- | -- | -- | -323,792.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Ocugen Inc | 9.33m | -49.67m | 262.45m | 65.00 | -- | 6.44 | -- | 28.14 | -0.1839 | -0.1839 | 0.0351 | 0.14 | 0.1365 | -- | -- | 143,492.30 | -72.71 | -83.56 | -90.53 | -97.79 | -- | -- | -532.51 | -2,921.94 | -- | -- | 0.0663 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 264.12m | 82.00 | -- | 1.31 | -- | -- | -- | -- | -- | 8.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.001 | -- | 579.21 | -- | 51.15 | -- | -- | -- |
| Poseida Therapeutics Inc | 150.86m | -60.76m | 264.13m | 350.00 | -- | 3.03 | -- | 1.75 | -0.635 | -0.635 | 1.56 | 0.8953 | 0.5064 | -- | 12.88 | 457,145.50 | -20.39 | -40.70 | -27.58 | -47.72 | -- | -- | -40.28 | -233.49 | -- | -6.89 | 0.4032 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -174.01m | 274.50m | 75.00 | -- | 0.5987 | -- | -- | -2.07 | -2.07 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -31.67 | -5.90 | -32.99 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 5.23m | -216.39m | 278.96m | 285.00 | -- | 1.56 | -- | 53.35 | -0.7513 | -0.7513 | 0.018 | 0.4938 | 0.0175 | 0.6955 | 3.25 | 18,347.37 | -72.42 | -24.41 | -81.77 | -29.01 | 93.54 | 98.49 | -4,138.33 | -84.92 | 7.43 | -12.32 | 0.3588 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 279.86m | 17.00 | 4.36 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Rezolute Inc | 0.00 | -69.31m | 281.60m | 59.00 | -- | 2.37 | -- | -- | -1.27 | -1.27 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -58.64 | -50.36 | -62.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 283.06m | 145.00 | -- | 1.17 | -- | 8.41 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Data as of Nov 22 2024. Currency figures normalised to Artiva Biotherapeutics Inc's reporting currency: US Dollar USD
57.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 9.85m | 40.57% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 915.39k | 3.77% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 819.98k | 3.38% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 795.84k | 3.28% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 520.30k | 2.14% |
| Geode Capital Management LLCas of 30 Sep 2024 | 308.93k | 1.27% |
| Woodline Partners LPas of 30 Sep 2024 | 283.12k | 1.17% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 194.11k | 0.80% |
| RTW Investments LPas of 30 Sep 2024 | 148.84k | 0.61% |
| Logos Global Management LPas of 30 Sep 2024 | 145.09k | 0.60% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
